SpringWorks seeks EU approval for desmoid tumor treatment By Investing.com

Published on 29 Feb 2024 on Investing.com

SpringWorks seeks EU approval for desmoid tumor treatment

Read the rest of the article

Start tracking your investments with Statfolio

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to...

Insider Monkey · via Yahoo Finance 22 Nov 2024

Shareholders of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) will be pleased this week, given tha...

Simply Wall St. · via Yahoo Finance 15 Nov 2024

Release Date: November 12, 2024 For the complete transcript of the earnings call, please refer to...

GuruFocus.com · via Yahoo Finance 12 Nov 2024

SpringWorks Therapeutics Inc (NASDAQ:SWTX) is set to release its Q3 2024 earnings on Nov 12, 2024...

GuruFocus.com · via Yahoo Finance 11 Nov 2024

SpringWorks Therapeutics Inc (SWTX) reports robust financial performance and strategic progress,...

GuruFocus.com · via Yahoo Finance 9 Oct 2024

The transaction was documented in a recent SEC Filing. SpringWorks Therapeutics Inc is a...

GuruFocus.com · via Yahoo Finance 22 Aug 2024

Badreddin Edris, the Chief Operating Officer of SpringWorks Therapeutics Inc (NASDAQ:SWTX), sold...

GuruFocus.com · via Yahoo Finance 21 May 2024

On June 3, 2024, Julie Hambleton, Director at SpringWorks Therapeutics Inc (NASDAQ:SWTX), sold 4,...

GuruFocus.com · via Yahoo Finance 21 May 2024

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Call Transcript May 5, 2024 SpringW...

Insider Monkey via Yahoo Finance 6 May 2024

SpringWorks seeks EU approval for desmoid tumor treatment

Investing.com 29 Feb 2024